THOUSAND OAKS, Calif.,
Dec. 9, 2019 /PRNewswire/
-- Amgen (NASDAQ:AMGN) today announced the signing of a lease
with BioMed Realty for a new 240,000-square-foot Leadership in
Energy and Environmental Design (LEED) candidate facility in the
Gateway of Pacific campus development in South San Francisco. The new location,
currently under construction at Oyster Point, will house Amgen's
Bay Area employees focused on cardiometabolic, inflammation and
oncology, research.
"At Amgen South San Francisco, we are home to top scientific
talent, integrating human genetics with core biology and molecular
engineering to discover and develop first-in-class therapies," said
Amgen's South San Francisco
site-head Flavius Martin, vice
president, Research, Oncology and Inflammation. "The new location
will foster even greater collaboration across our strong scientific
team, accelerate the R&D process, and provide a venue for
increased engagement with the Bay Area's abundant scientific and
educational communities."
Amgen has been part of the vibrant South San Francisco biotech community for 15
years. The company's new home at The Gateway of Pacific campus will
be a facility that boosts collaboration via modern work and
laboratory spaces. The new site will include modular green wet labs
and green molecular lab design. It will provide a flexible and a
customizable state-of-the-art scientific research and development
facility to support scientific research.
In addition to enhanced R&D laboratory and office space at
the new nine-story facility, which is scheduled to open in early
2022, the new campus will house a variety of meeting spaces, an
amenity center that includes a number of dining options, a health
club and a variety of outdoor recreation areas.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be the world's
largest independent biotechnology company, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Forward-Looking Statements
This news release contains forward-looking statements that are
based on the current expectations and beliefs of Amgen. All
statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements,
including any statements on the outcome, benefits and synergies of
collaboration with any other company, including BeiGene, Ltd., or
the acquisition of Otezla® (apremilast), including
anticipated Otezla sales growth and the timing of non-GAAP EPS
accretion, as well as estimates of revenues, operating margins,
capital expenditures, cash, other financial metrics, expected
legal, arbitration, political, regulatory or clinical results or
practices, customer and prescriber patterns or practices,
reimbursement activities and outcomes and other such estimates and
results. Forward-looking statements involve significant risks
and uncertainties, including those discussed below and more fully
described in the Securities and Exchange Commission reports filed
by Amgen, including our most recent annual report on Form 10-K and
any subsequent periodic reports on Form 10-Q and current reports on
Form 8-K. Unless otherwise noted, Amgen is providing this
information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise.
No forward-looking statement can be guaranteed, and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products, including our devices, after they are on the market. Our
business may be impacted by government investigations, litigation
and product liability claims. In addition, our business may be
impacted by the adoption of new tax legislation or exposure to
additional tax liabilities. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the
U.S. government, we could become subject to significant sanctions.
Further, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors, or we may fail to prevail in present and future
intellectual property litigation. We perform a substantial amount
of our commercial manufacturing activities at a few key facilities,
including in Puerto Rico, and also
depend on third parties for a portion of our manufacturing
activities, and limits on supply may constrain sales of certain of
our current products and product candidate development. We rely on
collaborations with third parties for the development of some of
our product candidates and for the commercialization and sales of
some of our commercial products. In addition, we compete with other
companies with respect to many of our marketed products as well as
for the discovery and development of new products. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and
become a commercial product. Further, some raw materials, medical
devices and component parts for our products are supplied by sole
third-party suppliers. Certain of our distributors, customers and
payers have substantial purchasing leverage in their dealings with
us. The discovery of significant problems with a product similar to
one of our products that implicate an entire class of products
could have a material adverse effect on sales of the affected
products and on our business and results of operations. Our efforts
to collaborate with or acquire other companies or products, and to
integrate the operations of companies or in support of products we
have acquired, may not be successful. A breakdown, cyberattack or
information security breach could compromise the confidentiality,
integrity and availability of our systems and our data. Our stock
price is volatile and may be affected by a number of events. Our
business performance could affect or limit the ability of our Board
of Directors to declare a dividend or our ability to pay a dividend
or repurchase our common stock. We may not be able to access the
capital and credit markets on terms that are favorable to us, or at
all.
CONTACT:
Amgen, Thousand Oaks
Christopher Lalli, 650-457-3204
(Media)
Jessica Akopyan, 805-447-0974
(Media)
Trish Hawkins, 805-447-5631
(Media)
Arvind Sood, 805-447-1060
(Investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amgen-selects-location-for-rd-facility-in-the-south-san-francisco-biotechnology-hub-300971372.html
SOURCE Amgen